EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
November 15, 2023
Earnings Call Speaker Segments
Bianca Fersini-Mastelloni
executiveAndrea, please go ahead.
Nicola Fiore
executiveNo, hold on—let me go through the standard disclaimer first. One moment. Alright, alright. Good afternoon, everyone, and welcome to the conference call on El.En.'s financial results for the third quarter of 2023. This call is being recorded today, and at the end of it there will be a chance to ask questions. Joining me are Andrea Cangioli, El.En.'s Managing Director, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relations Manager. Before we start, please be aware that management will make a remark on this call regarding future expectations, plans and prospects, as well as forward-looking statements. Some statements made on this call—among them those dealing with the company's beliefs, plans, objectives, estimates, or expectation of possible future results or events—are forward-looking statements. Such forward-looking statements carry known or unknown risks, including general economic and business conditions, and condition, conditions in the industry in which the company operates, and they may be affected if the assumption proves inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements could differ materially from those expressed or implied by any such forward-looking statement. The company accepts no obligation regarding the contents, nor to update the forward-looking statements so as to reflect events or circumstances that may arise after the date hereof.
Nicola Fiore
executiveShould you have any questions, kindly post them in the chat for Bianca Fersini Mastelloni, and she will be glad to introduce you in the order that bookings were received. That said, at this point I'd like to hand the call over to Andrea Cangioli. Andrea, please go ahead.
Andrea Cangioli
executiveI want to thank Nicola and Bianca, and I appreciate all of you for being on this call following the publication of our third quarter and nine-month financials report as of September 30, 2023. As Nicola mentioned, Enrico Romagnoli is here with me on this call, and he will take a deep dive into the financials. Nine months in, our revenues are posting a modest gain versus the equivalent periods of 2022, whereas income from operation is running behind last year's performance. That shortfall, on a consolidated basis, got larger during the third quarter, which showed an overall decline in sales relative to the third quarter of 2022, along with a matching drop in EBIT. The consolidated financial results mirror a varied set of performances across our different market segments and market regions, and that deserves a general mention before Enrico gives you the details shortly. The medical sector posted interesting growth over the prior year, gained from rising gross margins, and despite higher sales and marketing expenses, also improved its performance in terms of income from operations attributable to the sector. We are pleased with these results from the medical sector, and I would like to offer a couple of comments about them.
Andrea Cangioli
executiveFirst, they're surpassing what we had anticipated so far. Second, as expected, revenue growth is steadily decelerating as the year goes on. New order intake is still solid, yet the portion of period sales coming from long-term planning has declined, and demand on average reflects visibility of roughly 60 to 90 days, matching what occurred before the pandemic. The effects of broad uncertainty in the overall economic climate haven't helped improve conditions specific to the group's end markets. What we're seeing in our marketing, I'd say, is fairly described as a normalization phase unfolding after the post-pandemic euphoria. Versus the exceptional 2022, even the business segments posting the best results are easing their acceleration. In some cases, they're easing their pace too. Turning attention to the industrial sector, at this stage it's clearly more impacted by the general economic difficulties of the moment, but allow me to go a bit deeper into market dynamics. The western part of our sheet metal cutting business continues to post a robust rise in sales and profit—profits above 2022—although the third quarter showed a slowdown.
Andrea Cangioli
executiveIn the Italian side of the business, this was both foreseeable and expected, because the tax incentives for machinery investments, which go by the name Industry 4.0, are winding down. Those tax cuts previously gave sales a boost. At this point we're in a rebound phase, and it will be absorbed before long. We're putting substantial effort into broadening sales opportunities across international markets, and we're seeing notable success there. Our expectation is that we can partly offset the decline in domestic sales through a sharp rise in international sales. Fully offsetting the impact next quarter is probably beyond reach. The Chinese side of the business is still fighting to break out of the slump we're going through. You can see the slowdown clearly across the whole market and in our own results too. Heightened competition in the sheet metal cutting laser system market has forced heavy pressure on both price and margin, which, at roughly unchanged production volumes, pushed revenues and gross margins down and drove the bottom line firmly into the red. The measures we've taken to keep the business from posting a fourth consecutive loss quarter center mainly on improving purchasing and manufacturing efficiency, so we can reach the lower cost of goods sold levels required to grow sales and gross margins.
Andrea Cangioli
executiveA major push is underway to grow export sales, since those sales reach markets where competition is weaker and thus carry better margins. You can see that push in both units of our sheet metal cutting business, Cutlite Penta and Penta Zhejiang, as they go after the international market with a shared aim of relying less on their own domestic markets. Along those lines, I want to note that last week — the second time this year, following Chicago's Fabtech in October — our sheet metal laser cutting company took part in a trade fair with success. That was EuroBLECH in Stuttgart, where we exhibited at two separate stands: the Cutlite Penta systems made 100% in Italy, and the hybrid Italian-Chinese systems sold under the HL brand, which was created specifically for that purpose. As for the IPO plans involving the laser cutting division, despite Cutlite Penta's excellent results, the financial results after the third quarter of 2023 were weak because of the losses in the Chinese entities. That makes it less likely they can begin the listing process in the short term, and it raises the contingency that the private equity funds that invested in Penta Zhejiang with a view to the IPO may avail themselves of the right to exercise the withdrawal option provided in the event of failure to achieve the IPO objective.
Andrea Cangioli
executiveTurning to the other industrial-sector activities, we're really pleased with how quickly Lasit is growing revenue in laser marking, helped along by its distribution footprint expanding through its four sales subsidiaries. The first subsidiary, launched in Poland, is already accretive in 2023 to date. The Spanish and German subsidiaries are only in their very first quarter of operation; they're adding to sales volume but remain loss-making on operations. The U.K. facility has only just begun its activities. One very positive — a very positive line in the third-quarter financial performance is that the group delivered a significant return to cash generation, which drove an improvement of roughly EUR 22 million in the net financial position, taking it to EUR 32 million, versus EUR 10.2 million at the start of the quarter. The specifics of the net working capital movements show a reduction in trade receivables alongside a rise in inventory and trade payables. Down payments received and given still moved negatively during the quarter, by about EUR 3 million. That trend is consistent with what we expect for improvement in this financial metric across the second half of 2023.
Andrea Cangioli
executiveCapEx was definitely lower than in 2022, based on planning that doesn't account for this 2023, the capacity investment density and intensity seen in recent years. A few words about new products and the release pipeline, which, as you know, is the foundation of our competitive strategy. This time, I'll begin with the industrial world. As I said earlier, we're launching a new product range of laser cutting systems under the Italian brand HL, which for Western markets too combines Chinese cost effectiveness with selected Italian key components, with the aim of approaching the mid-lower end of the market with an offer suited to its needs and capabilities. For the medical market, the second half of 2023 and the year 2024 will bring an increase in the release of new products that in late 2022 and early 2023 had to slow down because of the contingent involvement of the R&D departments in one-time projects, such as support for re-engineering around missing components, and the commitment to modify products and support documentation in compliance with the new MDR regulations. For now, I'd like to mention the release of the PRO line, three new products for hair removal, pigmented lesion, and body shaping.
Andrea Cangioli
executiveAdditional systems are also slated to launch in the U.S. market, among them a body shaping device and a hair removal device meant to strengthen our distribution partner, which had a somewhat difficult 2023 because market conditions were more challenging. A final note regarding the flood that struck the area around Florence earlier this month. The El.En. facilities were unaffected, whereas the premises of our company, OT-LAS, took in roughly 70 cm of water and sustained serious damage to inventory, laser systems in progress, tools and office equipment. In addition, a key subcontractor of Cutlite Penta and a neighbor of OT-LAS experienced flooding at the same level and reported damage to several sub-assemblies owned by Cutlite and kept in their workshop. We hope to salvage some of the damaged material. It is therefore still too early to compute a new figure for the damages, as well as the possible recovery via insurance or government support. The worst aspect of the flood's impact is that many of our employees, of ours, who live on ground floors or use underground garages, have suffered severe damage to their personal property. Before I hand over to Enrico, I would like to note that with respect to the guidance released alongside the press release, which I will confirm shortly, the potential effect of the flood damages has not been factored in.
Andrea Cangioli
executiveThanks, Enrico. Go right ahead.
Enrico Romagnoli
executiveThanks, Andrea. I'll offer a remark about our latest financials. During the opening nine months of 2023, the medical sector posted a 6.4% gain, whereas the industrial sector declined 4.1%. Consolidated revenues came to EUR 493 million, which is 1.8% higher than the EUR 484 million recorded in the corresponding stretch of 2022. Across the nine months of 2023, the softness of the U.S. dollar, RMB, and JPY versus the EUR produced a cumulative negative effect on growth of roughly 2%, equal to EUR 9 million in absolute terms. Gross margin for the nine months was EUR 187.2 million, up 4.3% from EUR 179.5 million as of September 2022. That gain outpaced sales, reflecting recovery in sales margin from 37.1% to 38%. Over the nine months, sales margin improved in the medical sector, chiefly because of a better mix of products sold, and also because price increases offset higher material costs. In the industrial sector, though, it declined, largely due to difficulties in China — on the Chinese market — which unfavorable local economic conditions have made increasingly competitive.
Enrico Romagnoli
executiveOperating expenses went up and — sorry — the effect on sales rose from 8.6% to 9%. The primary driver is sales and marketing costs tied to trade fairs and congresses, pushed by both the medical and industrial businesses. Staff costs climbed by EUR 10.5 million, which also lifts the impact on sales from 14.5 to 16.4. Expenses for stock options and share-based payments to employees added to that increase. In 2023 the figure was EUR 2.8 million versus EUR 0.8 million in 2022, and the effect on average margin was 0.2% in 2022 and 0.6% in 2023. As of September 2023, the group employed more than 2,100 people, consistent with December 2022, and the additions came mainly from Asclepion in Germany and Quanta System in Italy, while headcount at the China company is coming down. EBITDA for the first nine months was positive at EUR 61.9 million, 8.4% lower than the EUR 67.6 million posted in 2022, and its impact on turnover fell from 13.9% to 12.6%. Depreciation and other accruals rose on account of investments made over recent years and a bad debt reserve, while they declined for warranty expenses, largely because of slower turnover in China.
Enrico Romagnoli
executiveThe hit to turnover is still 2%. At the close of the nine months of 2023, EBIT came in at a positive EUR 51.8 million, a decline of 10.6% from the EUR 57.9 million recorded as of September 2022, while the EBIT margin on sales fell from 12%-10.5%. Income before taxes for the nine-month period was positive at EUR 50.9 million, versus the EUR 57.9 million as of September 2022, with an impact on sales of 10.3%, compared with 12% in the same period of 2022. Pre-tax income in September 2023 took a negative hit from Chinese activities. As of September 2023, the Chinese pre-tax result was negative EUR 7.5 million, against income of EUR 2.2 million last year. On the net financial position side, the group stood at a positive EUR 32.1 million at the end of September 2023, lower than the EUR 75 million at the start of the year, yet above the June 2023 level, when the net financial position was around EUR 10 million. We also note that non-current assets include midterm liquidity, liquidity investment of EUR 23.6 million, and therefore that amount is excluded from the net financial position. Through the third quarter, the medical sector's trend remained positive.
Enrico Romagnoli
executiveSales rose 2%, whereas the industrial segment fell 17%. Total turnover came to EUR 147.4 million, a decline of 6.3% from the EUR 157.4 million posted in the same quarter of 2022. EBIT for the quarter stood at EUR 12.9 million, an 8.8% margin on sales, versus EUR 60.6 million in the same period of 2022, a decrease of 22%. Turning to cash flow in the third quarter of 2023, the group went back to generating cash, producing cash from operating activities and improving its net financial position by more than EUR 20 million during the period. Inflows from operating activities drove this outcome, along with the shrinkage of net working capital and a limited investment volume, below what had been seen in the recent past. This pattern matches the guidance given recently on cash generation and on how working capital used for operating activities would evolve, which anticipates a reversal of the trend in the second half of 2023 relative to what happened in the first six months of the year. In the medical sector, revenues reached EUR 287.9 million, up 6% from the last nine months of 2022.
Enrico Romagnoli
executiveWe saw sustained growth across nearly every application segment, with the one exception being the system for aesthetic applications, which posted a slight decline. A handful of significant accounts underperformed, and that drove the drop in business volume for hair removal, whereas sales in the anti-aging application kept posting rapid growth. The strong momentum in sales of the system for surgical applications carried on, holding growth at close to 30% alongside turnover of roughly EUR 56 million, versus EUR 43.8 million in the same period of 2022, consistent with our forecast and with the gradual rebound following the COVID-era slowdown, which hit harder here than in other segments. Within surgical applications, urology systems make up the largest portion of turnover and are likewise the fastest-growing. The therapy segment also extended its growth, posting turnover of EUR 11.9 million against EUR 11.6 million in the third quarter 2022. After-sales service and consumable revenue grew more over the nine months than system revenue did, helped by growth in the installed base, which naturally brings a larger volume of technical assistance and consumable usage, particularly in urology, where each surgery calls for a sterile optical fiber, nearly always single-use.
Enrico Romagnoli
executiveIn the first nine months of 2023, the industrial application sector saw a 4.1% decline, driven by weakness in the Chinese market, which was the group's primary market in this sector. Revenues came in at roughly EUR 205 million, versus EUR 213.8 million in 2022. The laser cutting segment posted turnover of EUR 166.2 million, against EUR 180.5 million in the nine months of 2022, a drop of 8%. After years of steady, rapid expansion that brought it to about 81% of sales in the industrial sector, the cutting segment logged lower revenues for the nine months versus the prior year. Turnover from Chinese operations, in fact, fell 23.5%, also hit by a 6.6% exchange rate effect stemming from the weakness of the Chinese renminbi against the euro. Cutlite Penta's sales growth of 14.4% in the first nine months, despite a decline of -5.8% in the third quarter, was not enough to keep segment turnover growing. The marking segment, thanks especially to Lasit's activities, picked up pace in the quarter and posted revenue growth of 18%, followed by the laser sources sector, which grew 10%.
Enrico Romagnoli
executiveAfter-sales service and consumable revenue rose 17%, driven by growth in the installed base. Looking at sales trends by macro geographic region for the fuse sector, the strongest showing came in overseas markets for the medical business, while in the industrial business we saw excellent sales in Italy and Europe, offset by a slowdown in the rest of the world stemming from weaker sales in the cutting sector at the Chinese company. Please go ahead on the 2023 guidance.
Andrea Cangioli
executiveApologies — I didn't have that in front of me. So through the first nine months, the medical division managed to keep both revenues and EBIT growing, while the industrial division saw a modest dip, driven by results out of China. The present macroeconomic backdrop is shaped by rising interest rates, inflation, and global instability, made worse by armed conflicts. The group reaffirms its solid competitive position and its tangible capacity and ability to capture the opportunities its market will keep presenting in the years ahead. Regarding how this fiscal year will close, the aim is to hold turnover to modest growth versus the prior fiscal year, while keeping the EBIT shortfall against 2022 in the same proportion seen during the first nine months. That concludes our prepared remarks, and we're ready to take your questions.
Bianca Fersini-Mastelloni
executiveAndrea, there's a single question on the list, and it comes from Giovanni Selvetti at Berenberg. Go ahead, Giovanni. Thank you.
Giovanni Selvetti
analystHey everyone, are you able to hear me?
Andrea Cangioli
executiveYes.
Bianca Fersini-Mastelloni
executiveCorrect.
Andrea Cangioli
executiveHi there, Giovanni.
Giovanni Selvetti
analystHello there. Thanks for the question. I've got several. First, regarding the industrial division: could you quantify what the Chinese company did to EBIT in Q3? As I recall, it was roughly -4 in the first half, so I just want a sense of whether things are getting worse. And if they are, where is the pressure greatest — volume or price? Still on China, please give us some more color on the various approaches the different private equity firms are taking. If I recall correctly, the capital increase came in separate tranches. So could you remind us what the cash outs would be if every private equity decides to withdraw? And third, you said Cutlite Penta might offset part of the decline in Italy through exports abroad. Which markets are you mainly targeting there? Moving to medical: you said they're exceeding your expectations. Again, I'm wondering whether that's on pricing or on volumes, since I can see their gross margin improved. And in the press release, you mentioned it's a better mix of products sold, so I'm wondering whether it's fair to say that raising prices may be easier in surgical than in aesthetics.
Giovanni Selvetti
analystComing back to the aesthetics point one more time — you said results there took a hit from some softness in hair removal tied to issues with certain customers. Are those the same ones you brought up earlier in the first half, and if so, where does that stand and what's happening? Thank you.
Andrea Cangioli
executiveAlright, thanks, Giovanni. I hope I can keep track of all of it, but let's begin with China. I think — and I'm not sure whether Enrico brought this up — there was negative EBIT of roughly EUR 6 million, which implies around EUR 2 million of negative EBIT in the third quarter. Those figures are more or less in proportion to what we saw during the first half. Turning to private equity, the total investment made by private equity came to approximately EUR 20 million, but we have various agreements — or rather, various amendments to those agreements — that have caused us at this point to book roughly EUR 14 million as a financial liability, meaning a potential liquidation right. Enrico, please correct me if—
Enrico Romagnoli
executiveYes, yes, yes. That is right.
Andrea Cangioli
executiveSo here’s where things stand right now. That debt already sits within the net financial position, meaning we carry a financial liability toward those private equity funds that hold the right to redeem their shares. Yes, when I say the medical market has performed beyond what we expected, what I mean is this: when we put together our 12-month budget — the one we used as the basis for releasing our yearly guidance — we were anticipating a robust rise in industrial revenues and industrial profits, both in Italy and in China, along with lower profitability in the medical business, and a very, very small gain, or roughly flat, something basically in line with 2022 in the medical field. That applies to the full year, which isn’t finished yet.
Giovanni Selvetti
analystYeah.
Andrea Cangioli
executiveRight now, we're seeing a decent revenue bump in medical, along with a rise in the absolute value of income from operations, and given the mix we set out in our original budget, that's beating what we expected. What clearly isn't beating expectations — in fact it's far off from them — is how China has performed. If you set aside that very weak China result, our financials for 2022 would have looked entirely different, and probably would have come in above our expectation. That's the reason I say we're doing better than expected. On the margin increase, a few components feed into the gross margin improvement. Surgical sales are higher, and those currently carry a higher average gross margin. Then there's the price increases we managed to push through at the start of the year with certain customers. And there's the slowdown at certain large customers that carried lower margins, so the net effect is a gross margin increase. This connects to your question about the large accounts, or the large accounts that were slower this year than in 2022.
Andrea Cangioli
executiveYes, I can confirm those are mostly the American accounts. The ones we're primarily discussing are the US accounts, and they were significantly slower compared with 2022. That's what involved the hair removal accounts — the hair removal account. The good news on this front is that you're seeing aesthetics come in roughly flat versus last year. So, we experienced a deceleration in hair removal driven mainly by those accounts, and also by some softness in certain markets such as the Middle East. However, we performed very, very strongly in other market verticals, particularly across anti-aging overall. The anti-aging business has been performing extremely well, both with our ablative systems, CO2 and erbium, and with our picosecond systems for the Far East. I think I've addressed all of your questions.
Giovanni Selvetti
analystI might have missed that answer, but let me also ask whether Cutlite Penta is exporting at this point, offsetting the Italian—
Andrea Cangioli
executiveOh, yes, yes, yes. Yes, sorry—sorry, I forgot. Cutlite Penta set up a related subsidiary over in France, and that became the biggest market in Europe. It also established a related company in the United States, which in the coming months will be by far the largest market abroad. So I'd say the top markets for Cutlite Penta are the United States, France, and Spain. After that, we have lower sales volumes across Europe and in other countries.
Bianca Fersini-Mastelloni
executiveAndrea-
Giovanni Selvetti
analystAlright.
Bianca Fersini-Mastelloni
executiveOh, my apologies.
Giovanni Selvetti
analystI appreciate that.
Bianca Fersini-Mastelloni
executiveAlright, we’ve got a question coming from Manon Coulon at Erasmus Gestion. Go ahead, Manon. Thanks.
Manon Coulon
analystHello there. Hello, Bianca. Hello, Enrico.
Bianca Fersini-Mastelloni
executiveHello.
Manon Coulon
analystThanks for taking my question. I actually have a few. First off, could you walk us through a little more detail on the sales growth in Q3? How much did the price increase contribute, and what about the currency effect? Enrico, I know you mentioned something about the renminbi's impact on industrials, but I'd like to hear about all the currencies at the group level. My second question is about staff costs. If I'm reading this right, I see a decline from Q2 to Q3, going from EUR 29 million down to slightly below EUR 26 million. What drove that, and how should we think about Q4? The third one concerns the Congress in Singapore, related to your season marketing. I believe there was a strong budget for 2023 that won't be returning in 2024. How many euros are we talking about here? And on your visibility for 2024, what should we expect following Q3 2023, which was quite unexpected? What's your thinking for 2024? Thank you.
Andrea Cangioli
executiveManon, I couldn’t really hear you—sorry. What was your last question about—what exactly was unexpected in 2023? What—
Manon Coulon
analystIt really comes down to how much visibility you’ve got into the market and into your sales for 2024.
Andrea Cangioli
executiveRight, the visibility. The visibility. So then, in Q2 and Q3, what moved from EUR 29 million down to EUR 26 million? Sorry, I honestly couldn't hear you. There's an echo and your voice is coming through softly. What went from 29 to 26? What was it that changed from EUR 29 million to EUR 26 million? I wasn't able to make it out.
Manon Coulon
analystMy apologies — that figure was actually for staff costs.
Andrea Cangioli
executiveThe?
Manon Coulon
analystExpenses related to personnel.
Andrea Cangioli
executiveThe what?
Manon Coulon
analystOn employee costs — employee expenses.
Giovanni Selvetti
analystAndrea is an employee.
Andrea Cangioli
executiveOh, right — how many people we have on staff.
Giovanni Selvetti
analystPersonnel expenses.
Enrico Romagnoli
executiveNo, no, no. It's the staff costs.
Manon Coulon
analystExpenses related to personnel.
Enrico Romagnoli
executivePersonnel expenses. Personnel expenses.
Andrea Cangioli
executiveOn staff costs — staff costs — regarding 2024 visibility, let's take the last question first. What we can see for 2024 stems from our sensation considerably more than was the case a year earlier. As I said previously, during the last two years we booked enormous orders to be planned across the year. Bookings on that massive scale are no longer happening. Incidentally, that kind of modality came to an end in the first months of 2023, so we are back to the standard order visibility of around 90 days, as I mentioned earlier. Thus, at this moment, the visibility we have is not much beyond our customers' forecast — forecasts, let's say, that are not fixed orders. Visibility right now supports a good year, but we are not yet in a position to provide any further detail. On employee cost, Enrico, I do. Did you understand? So you said the cost is decreasing in the third quarter versus the second quarter.
Manon Coulon
analystYes, yes, that’s what I said, though maybe—maybe I’m mistaken—but what I was looking at was EUR 29 million in Q2 2023, and I saw EUR 26 million in 2023, in Q3 2023. Sorry. So perhaps layoffs, or I don’t know.
Andrea Cangioli
executiveCould you bring that slide back up for Enrico, please?
Enrico Romagnoli
executiveOne moment, please. I'm bringing the slide up now.
Andrea Cangioli
executiveAnd at the same time
Enrico Romagnoli
executiveAbout-
Andrea Cangioli
executiveOn that first question about price increases, their impact on margin, and how much of the effect comes from price increases: in medical, the effect of price increases is probably worth about 1 point of percentage of increase, since we applied a 10% price increase in medical, but a fairly small part of the population basically absorbed and accepted this. And then, typically, we have new products, to which the concept of increase itself does not apply. So I hope I answered your first question. Now-
Enrico Romagnoli
executiveSorry to jump in — a question on staffing, please.
Andrea Cangioli
executiveThis is the thing you brought up.
Enrico Romagnoli
executiveRegarding personnel, you can observe that the figure stands at EUR 25.7 million for Q3 of 2023, whereas staff cost was EUR 29 million in Q2 and EUR 26 million in Q1. During the first half of 2023, employee headcount exceeded the level at the close of September, since a workforce reduction took place, primarily within the Chinese company. Furthermore, one must factor in that August falls within Q3, which for the European company at least is a holiday period. As a result, staff cost showed a natural decline in Q3 relative to the other quarter.
Andrea Cangioli
executiveI’ve got two-
Enrico Romagnoli
executiveThat's likely the primary factor.
Andrea Cangioli
executiveI have two points to make here. First, a general one. Staff costs went up in the opening months of 2023 versus 2022, since throughout 2022 those costs kept rising steadily, which meant the staff cost figure at year-end was considerably above where it stood at the start of the year. As a result, the comparison against the first months of the year reflects a steeper increase. On the absolute figure, Enrico, I think there was roughly EUR 800,000 in one-time cost in China related to stock-based compensation during the first quarter, and that does not repeat in the quarters that follow.
Enrico Romagnoli
executiveJust to clarify one thing — yes, that's right for Q1. It came in at roughly EUR 1 million, actually slightly under EUR 1 million.
Andrea Cangioli
executiveYeah, I mean, this was a one-time charge on the Chinese books.
Enrico Romagnoli
executiveYeah.
Andrea Cangioli
executiveWe aren't discovering any additional ones in Q3. Manon, did we capture all of them, or—sorry, my mistake?
Manon Coulon
analystPossibly a couple more questions. What about the currency effect for Q3, at the group level — how does that look for the group?
Andrea Cangioli
executiveThe what?
Enrico Romagnoli
executiveNow, on currency effects. For the nine-month period, when we consolidate foreign currencies into U.S. dollars, RMB, and JPY, the total hit to sales came to EUR 9 million, which dragged the growth rate down by 2%. I don't have the Q3 figure in front of me, but give me a moment and I'll work it out.
Andrea Cangioli
executiveAll right, and while Enrico is working that out, did you have another question?
Manon Coulon
analystYeah, about the Singapore Congress — because I believe you brought that up, and last time you had this, I think it's focused on dermatology. You had a congress held in Milan, so the budget came in much lower compared with Singapore, and that shouldn't happen again in 2024. So, what budget was set for this congress?
Andrea Cangioli
executiveIs that for one congress, or does it cover the entire congress expense?
Manon Coulon
analystRegarding the Singapore item. The dermatology item in Singapore.
Andrea Cangioli
executiveI can't recall that figure, honestly. I truly couldn't say. What I can tell you is that our budget is very broad and very costly. Our expenses run roughly EUR 3 million above 2023. The big congresses are no longer on the calendar. We used to have them. That said, right now we're at a costly congress in Hong Kong — Asia Cosmoprof. As for what a single congress costs in detail, I think Singapore on its own came to around EUR 250,000 all in. What that covers — I mean, a congress's costs break down into these accounts: buying the space through the congress organizer, building the stand, flying our staff out and putting them up, flying there and staying there, and paying lecturers for their performances at a congress. Singapore, I believe, has been far and away the priciest congress we've taken part in over recent years. The next major and very costly congress will be IMCAS in Paris at the end of January, though naturally the flight cost will at least be far, far below what Singapore ran. And then on sales and marketing expense, travel — we have to travel a great deal. Sales aren't arriving on their own during this period.
Andrea Cangioli
executiveWe need to stimulate the market. A portion of the travel involves nations where we're launching new markets. Certainly, a significant event is scheduled in India for early December, designed to unlock the Indian market for us, which up to now hasn't been a meaningful market for our medical products. So we're investing heavily in sales and marketing, yet that matters greatly because it gives us the chance to broaden our international footprint further.
Manon Coulon
analystThanks a lot, Andrea.
Enrico Romagnoli
executiveRegarding the effect in Q3, Manon, foreign currency produced a negative impact of EUR 4.2 million for that quarter. So across the nine months it came to EUR 9.1 million, and for the three months it was EUR 4.2 million.
Manon Coulon
analystThanks a lot, Enrico. That was really clear.
Enrico Romagnoli
executiveGlad to help.
Bianca Fersini-Mastelloni
executiveAndrea, there's an additional question coming in from Carlo Maritano at Intermonte. Carlo, go ahead, please.
Carlo Maritano
analystHello, and good evening to everyone. From where I stand, I have three questions. The first concerns CapEx. Over the nine months, we have observed a fairly significant decrease relative to last year. I would like to know what level of CapEx we should treat as normal in the years ahead, assuming no extraordinary CapEx. My second question relates to the marketing business. During the third quarter, it recorded a certain deceleration versus the prior quarter. Is this a matter tied to Industria 4.0, or is something else behind it? Lastly, could you give us an update on the acne treatment product — how the first phase is progressing, and whether there is any news you are able to share with us?
Andrea Cangioli
executiveCarlo, what came next? Sorry — my speaker is really poor. Your second question was about what, again?
Carlo Maritano
analystYour next question concerned capital expenditures.
Andrea Cangioli
executiveNo, this is the first one.
Carlo Maritano
analystNo, no, my apologies. I mean the marketing business. My mistake.
Andrea Cangioli
executiveOn the marketing side of things. All right.
Carlo Maritano
analystRegarding how things went in the third quarter, if that ties back to Industria 4.0, or if it's—
Andrea Cangioli
executiveAlright.
Carlo Maritano
analystThat covers any other explanation for the performance. Thank you.
Andrea Cangioli
executiveAll right, CapEx. Yes, capital expenditure is decelerating. What I mean is, we invested heavily in expanding our facilities, and that — along with the growth in headcount — has pushed up what you might call our baseline CapEx, which I'd say now sits at roughly EUR 8 million to EUR 10 million. In fact, for this year we'll land somewhere between EUR 16 million and EUR 18 million, and of that, EUR 5 million to EUR 6 million reflects additional spending and further investment in new buildings, whereas the remainder covers toolings, cars and similar items — the EUR 8 million to EUR 10 million band being the ordinary level of investment we require simply to keep things running, so to speak. The marketing business is performing very well across all of Italy, and even stronger abroad, thanks to the impact of the new subsidiaries. You're correct that they're less exposed to the 4.0 scheme. My sense is that above all they're addressing a mandatory need. The ticket size is smaller, I mean, so naturally everyone would rather have tax relief, let's say, attached to their investment. But in the capital business, we're discussing investments on the order of EUR 300,000 to EUR 600,000-EUR 700,000.
Andrea Cangioli
executiveWhen it comes to laser markets — the standard laser market — the price range is EUR 30,000 to EUR 40,000. That's a fairly sizable investment, I mean, but it isn't — while with a large investment a tax cut can change the deal, for a device of that type it isn't essential. Finally, Accure — we are, the Accure company is moving forward with the preliminary launch of its devices. We're seeing the first happy customers using our devices. There are roughly a few dozen of them. In this preliminary launch, the count of units placed on the U.S. market is probably around 30, 30 units, and that will rise through the end of the year. Naturally, it is a test launch. Some adjustments to the device are also needed, now that we've begun working on it intensively. But on the whole, acceptance of the systems and customer satisfaction are high. So we hope all the conditions are in place to move into the next phase, which will be launching the business at a larger scale, and that phase must also include a funding stage. Because, as you recall — as you may recall — the group took part in the technical development of the device, but did not take part in funding the clearance expenses and the marketing expenses, which were left as a burden on the affiliated company, Accure Acne, and on its funding partners.
Andrea Cangioli
executiveHello?
Bianca Fersini-Mastelloni
executiveHi there. Carlo, are you doing okay? Is everything fine?
Carlo Maritano
analystYes, that's fine. Are you able to hear me?
Bianca Fersini-Mastelloni
executiveYeah, I can hear you.
Carlo Maritano
analystAlright, thanks.
Bianca Fersini-Mastelloni
executiveAll right, Andrea — we don’t have any further questions on our list. I’d like to ask the floor whether anyone else has a question.
Andrea Cangioli
executiveYes.
Bianca Fersini-Mastelloni
executiveOh?
Analyst
analystMay I?
Bianca Fersini-Mastelloni
executiveYeah. Yes, Andrea.
Analyst
analystYeah.
Bianca Fersini-Mastelloni
executivePlease continue.
Analyst
analystOkay. Hello, and good afternoon, everyone. Real quick, Andrea — I didn't quite hear which unit it was that the flooding in the Florence area affected, and the supplier as well, and what the actual effect is on your production flow, or whether there's any effect at all on what you expect for sales and activity overall? Thank you.
Andrea Cangioli
executiveWhat I mean is that the units involved are OT-LAS. OT-LAS is a company generating roughly EUR 5 million in revenues across the year, and it operates a small factory of approximately 8,600 square meters. Over the weekend, they cleaned up that factory. I mean, every employee showed exceptional commitment when it came to cleaning the ruined facility. We are not yet fully back to working, but essentially, we have absorbed the shock when it comes to our producing capabilities. Regarding damage, it is early to say, since many toolings and many devices have been damaged, but there is a chance we can recover. So understanding the full extent of the damage will take a bit longer. The other partner that was damaged is a subcontractor of Cutlite Penta. They assemble on behalf of Cutlite Penta, and the materials they assemble are owned by Cutlite Penta. As a result, the flood ruined the materials at our subcontractor's place, yet ownership of those materials rests with Cutlite Penta. And so here again we will have to see two things. First, how much of these damaged materials we will be able to recover. Second, what kind of insurance coverage we can have in order to recover the damage we suffered.
Andrea Cangioli
executiveAs far as I can tell, none of this damage is material, especially when you compare the size of the damage to the consolidated total — although for an individual activity, it could matter over a brief span. And I don't think we'll face any meaningful obstacles where our manufacturing capacity is concerned, also since… Cutlite Penta doesn't carry out production only at this site; they have their own manufacturing floor in Prato, and that one was untouched. They also have a second manufacturing floor in Valdelsa, which was untouched as well. This one was significant. Getting back to normal will probably take a while, but it shouldn't be a reason to alter production schedules in the near term.
Analyst
analystThanks. That's very clear. If I can, one final question. You managed to boost net cash through solid working capital management. Should we expect that to carry on into Q4 as well? Can you give us guidance on what you expect for the net cash level at year-end?
Andrea Cangioli
executiveWe're putting strong effort behind that. What we expect is to keep going along this path — bringing inventory down and lowering net capital, both in terms of asset value and in terms of the effect on sales. That's what we anticipate happening in the fourth quarter as well, which, incidentally, tends to be the most favorable one since it marks the close of the forecasting cycles. It's the close of the year. Cash-wise, the fourth quarter is usually a good one for us. This year, we'll have a disadvantage relative to other years. In Italy, we won't see the inflow of down payments for Industry 4.0, which in December had been a relevant cash inflow. Last year — since Industry 4.0 is not relevant and is very marginal — we are not going to see an increase in down payments during these final months. But we do expect to see the net cash position improving over these final months.
Analyst
analystAnd if I could just ask, is your supply chain and, say, logistics network now back to business as usual — so is it back to how things were in 2019, or how do you view the situation at this point?
Andrea Cangioli
executiveWell, I mean, when I mention a normalization process following the hype, that applies to our markets and, on the flip side, it applies to our supply markets too. Our relations are back to normal. We buy things, and they deliver on decent terms. We buy things, and we're able to find them. They're available. There are exceptions — a few exceptions remain on certain electric components — but on the whole, we don't have to push the supply chain to obtain material, since the supply chain is no longer operating at full capacity.
Analyst
analystMuch appreciated.
Bianca Fersini-Mastelloni
executiveThat appears to be all the questions we have listed. Are there additional questions from the floor? Alright, if nothing further has come in, we'll bring the conference to a close. Should any questions need looking into, please feel free to reach out to Enrico Romagnoli. He'll be glad to respond to your question. Thanks for joining this conference, and we hope to see all of you again next time. Good afternoon, everyone. Bye. Bye-bye.
Enrico Romagnoli
executiveThanks. Goodbye.
Andrea Cangioli
executiveAppreciate it. Goodbye.
Enrico Romagnoli
executiveTake care, everyone. Appreciate you all.
Bianca Fersini-Mastelloni
executiveThank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.